143 results
Page 2 of 8
8-K
EX-99.1
nfiic
3 Nov 21
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates
4:05pm
8-K
EX-99.1
kkrrjq06e y4pf15v
4 Oct 21
Other Events
8:40am
S-8
EX-99.1
lmknekou8ubhg
14 Sep 21
Registration of securities for employees
4:32pm
8-K
EX-99.1
sirjt9j9o8msa5trrx1
9 Aug 21
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates
8:10am
8-K
EX-99.1
x40hq1c28vezmo
13 May 21
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
8:25am
8-K
EX-99.1
zr006t3fg00 ubp
13 May 21
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
8:25am
8-K
EX-99.2
9m7ct6mzo5ab
11 Jan 21
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program
8:40am
8-K
EX-99.1
m2jvokh4wq
13 Nov 20
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain
8:40am
S-8
EX-99.1
k0t6q
5 Aug 19
Registration of securities for employees
4:53pm